Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Mineralys Therapeutics Inc (NASDAQ: MLYS) closed at $33.37 up 0.72% from its previous closing price of $33.13. In other words, the price has increased by $0.72 from its previous closing price. On the day, 1.36 million shares were traded. MLYS stock price reached its highest trading level at $33.92 during the session, while it also had its lowest trading level at $32.71.
Ratios:
For a deeper understanding of Mineralys Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 25.50 and its Current Ratio is at 25.50. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Jefferies on June 11, 2025, initiated with a Hold rating and assigned the stock a target price of $15.
On July 10, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.
On April 02, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $30.Goldman initiated its Buy rating on April 02, 2024, with a $30 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 09 ’26 when Rodman David Malcom bought 2,170 shares for $33.27 per share.
Rodman David Malcom sold 192,715 shares of MLYS for $6,749,109 on Jan 05 ’26. The Chief Medical Officer now owns 61,804 shares after completing the transaction at $35.02 per share. On Jan 02 ’26, another insider, Rodman David Malcom, who serves as the Chief Medical Officer of the company, sold 70,037 shares for $35.87 each. As a result, the insider received 2,511,919 and left with 69,188 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLYS now has a Market Capitalization of 2640900096 and an Enterprise Value of 2047272320.
Stock Price History:
The Beta on a monthly basis for MLYS is 0.52, which has changed by 2.565171 over the last 52 weeks, in comparison to a change of 0.19362879 over the same period for the S&P500. Over the past 52 weeks, MLYS has reached a high of $47.65, while it has fallen to a 52-week low of $8.24. The 50-Day Moving Average of the stock is -14.66%, while the 200-Day Moving Average is calculated to be 30.35%.
Shares Statistics:
For the past three months, MLYS has traded an average of 1.50M shares per day and 1196930 over the past ten days. A total of 78.97M shares are outstanding, with a floating share count of 56.38M. Insiders hold about 28.77% of the company’s shares, while institutions hold 79.79% stake in the company. Shares short for MLYS as of 1765756800 were 7948340 with a Short Ratio of 5.31, compared to 1763078400 on 6889251. Therefore, it implies a Short% of Shares Outstanding of 7948340 and a Short% of Float of 12.560001000000002.
Earnings Estimates
A comprehensive evaluation of Mineralys Therapeutics Inc (MLYS) is underway, with the input of 7.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.54, with high estimates of -$0.44 and low estimates of -$0.67.
Analysts are recommending an EPS of between -$2.13 and -$2.57 for the fiscal current year, implying an average EPS of -$2.4. EPS for the following year is -$2.31, with 6.0 analysts recommending between -$1.74 and -$3.03.
